Clinical trial
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
NCT02003209 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 18, 2014
- Completion date
- June 30, 2025
- Enrollment
- 315 (actual)
- Sites
- 732
Conditions
As the registry lists them; a condition with its own page is linked.
her2-positive breast carcinoma, hormone receptor-positive breast carcinoma, stage ib breast cancer ajcc v7, stage iia breast cancer ajcc v6 and v7, stage iib breast cancer ajcc v6 and v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7